These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32377702)

  • 1. Juglone potentiates BRAF inhibitor‑induced apoptosis in melanoma through reactive oxygen species and the p38‑p53 pathway.
    Li Z; Liu X; Li M; Chai J; He S; Wu J; Xu J
    Mol Med Rep; 2020 Jul; 22(1):566-574. PubMed ID: 32377702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Juglone potentiates TRAIL‑induced apoptosis in human melanoma cells via activating the ROS‑p38‑p53 pathway.
    Liu X; Chen Y; Zhang Y; Du J; Lv Y; Mo S; Liu Y; Ding F; Wu J; Li J
    Mol Med Rep; 2017 Dec; 16(6):9645-9651. PubMed ID: 29039537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF.
    Liu X; Li Z; Li M; Chai J; He S; Wu J; Xu J
    Oncol Rep; 2020 Jul; 44(1):360-370. PubMed ID: 32319656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells.
    Bauer D; Werth F; Nguyen HA; Kiecker F; Eberle J
    Cell Death Dis; 2017 Feb; 8(2):e2594. PubMed ID: 28151482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
    Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
    Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance
    Poudel M; Kim G; Bhattarai PY; Shin S; Zaraei SO; Oh CH; Choi HS
    Anticancer Res; 2022 Jun; 42(6):2911-2921. PubMed ID: 35641256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.
    Park SJ; Hong SW; Moon JH; Jin DH; Kim JS; Lee CK; Kim KP; Hong YS; Choi EK; Lee JS; Lee JL; Kim TW
    Am J Med Sci; 2013 Dec; 346(6):494-8. PubMed ID: 24051957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
    Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
    Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HI-511 overcomes melanoma drug resistance
    Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
    Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
    [No Abstract]   [Full Text] [Related]  

  • 12. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METTL3 induces PLX4032 resistance in melanoma by promoting m
    Bhattarai PY; Kim G; Poudel M; Lim SC; Choi HS
    Cancer Lett; 2021 Dec; 522():44-56. PubMed ID: 34530048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of superoxide and nitric oxide in BRAF(V600E) inhibitor PLX4032-induced growth inhibition of melanoma cells.
    Yu L; Gao LX; Ma XQ; Hu FX; Li CM; Lu Z
    Integr Biol (Camb); 2014 Dec; 6(12):1211-7. PubMed ID: 25363644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.
    Choi J; Landrette SF; Wang T; Evans P; Bacchiocchi A; Bjornson R; Cheng E; Stiegler AL; Gathiaka S; Acevedo O; Boggon TJ; Krauthammer M; Halaban R; Xu T
    Pigment Cell Melanoma Res; 2014 Mar; 27(2):253-62. PubMed ID: 24283590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
    Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
    PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Juglone induces apoptosis of tumor stem-like cells through ROS-p38 pathway in glioblastoma.
    Wu J; Zhang H; Xu Y; Zhang J; Zhu W; Zhang Y; Chen L; Hua W; Mao Y
    BMC Neurol; 2017 Apr; 17(1):70. PubMed ID: 28388894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
    Borst A; Haferkamp S; Grimm J; Rösch M; Zhu G; Guo S; Li C; Gao T; Meierjohann S; Schrama D; Houben R
    Cancer Lett; 2017 Sep; 404():70-78. PubMed ID: 28720543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.